Escolar Documentos
Profissional Documentos
Cultura Documentos
ABSTRACT
:
.
. :
MG
2009
. .2010
936 MG :
2.17/100,000 MG .
.) 14.16( 44.93 .
)90.3%( 845 MG
64,332,806 MG .
/ 68,731.63 ) 2,144,426.87(
.) 2,291.05(
. 10.45
MG
100,000/ 2.17 MG
:
.
.
Objective: To examine the prevalence of hospitalized
myasthenia gravis (MG), and to determine the factors
associated with poor outcomes of hospitalized MG
patients at a national level.
Methods: This study was based on a retrospective
design. We collected data of hospitalized MG
adults recorded by the National Health Security
Office, Bangkok, Thailand between October 2009
and September 2010. Clinical data and treatment
outcomes were examined.
286
OPEN ACCESS
www.neurosciencesjournal.org
www.neurosciencesjournal.org
287
Population
ages 18 and
over
Patient/100,000
Northern
8,871,705
220
2.48
Northeast
15,964,936
276
1.73
Central
11,896,555
391
3.39
6,287,474
49
0.78
43,020,670
936
2.17
Southern
Total
Table 2 - Factors affecting discharge status of hospitalized myasthenia gravis patients (N=936).
Variable
Improved
Gender
Male
242 (91.0)
Female
603 (90.0)
Age
18-29
138 (91.4)
30-39
201 (91.8)
40-49
204 (89.1)
50-59
177 (90.3)
60-69
93 (89.4)
70-79
23 (88.5)
80+
9 (81.8)
Insurance groups
Government welfare
95 (90.5)
Social welfare
183 (95.3)
Universal coverage
567 (88.7)
Hospital category
Primary
72 (72.0)
Secondary
175 (87.1)
Tertiary
491 (94.2)
Private
107 (93.9)
Regions
Northern
197 (89.5)
Northeast
240 (87.0)
Central
367 (93.9)
Southern
41 (83.7)
Pneumonia
No
778 (92.0)
Yes
67 (74.4)
Respiratory failure
No
660 (94.0)
Yes
185 (79.1)
Intravenous immunoglobins
No
840 (90.2)
Yes
5 (100.0)
288
Discharge Status
Not improved
Dead
n (%)
21 (7.9)
50 (7.5)
Total
3 (1.1)
17 (2.5)
266 (28.4)
670 (71.6)
(7.9)
(7.3)
(9.6)
(7.1)
(4.8)
(3.8)
(9.1)
1 (0.7)
2 (0.9)
3 (1.3)
5 (2.6)
6 (5.8)
2 (7.7)
1 (9.1)
151 (16.1)
219 (23.4)
229 (24.5)
196 (20.9)
104 (11.1)
26 (2.8)
11 (1.2)
6 (5.7)
7 (3.6)
58 (9.1)
4 (3.8)
2 (1.0)
14 (2.2)
105 (11.2)
192 (20.5)
639 (68.3)
27 (27.0)
22 (10.9)
18 (3.5)
4 (3.5)
1 (1.0)
4 (2.0)
12 (2.3)
3 (2.6)
100 (11.0)
201 (21.0)
521 (56.0)
114 (12.0)
19 (8.6)
34 (12.3)
11 (2.8)
7 (14.3)
4 (1.8)
2 (0.7)
13 (3.3)
1 (2.0)
220 (23.5)
276 (29.5)
391 (41.8)
49 (5.2)
56 (6.6)
15 (16.7)
12 (1.4)
8 (8.9)
846 (90.4)
90 (9.6)
41 (5.8)
30 (12.8)
1 (0.1)
19 (8.1)
702 (75.0)
234 (25.0)
71 (7.6)
0 (0.0)
20 (2.1)
0 (0.0)
931 (99.5)
5 (0.5)
12
16
22
14
5
1
1
P-value
0.399
0.072
0.040
<0.001
<0.001
<0.001
<0.001
0.999
www.neurosciencesjournal.org
Count
Length of stay
Mean
SD
846
90
8.50
28.74
14.31
34.59
Respiratory failure
No
Yes
702
234
6.35
22.74
10.22
28.74
IVIG treatment
No
Yes
234
230
4
22.74
22.30
48.00
28.74
28.35
44.12
Pneumonia
No
Yes
P-value
<0.001
<0.001
0.142
Adjusted odds
ratio
95%
confidence
interval
P-value
Hospital category
<0.001
Primary
1.00
Secondary
0.24
0.12-0.46
Tertiary
0.09
0.04-0.18
Private
0.28
0.09-0.84
Pneumonia
0.027
No
1.00
Yes
2.20
1.10-4.39
Respiratory failure
<0.001
No
1.00
Yes
4.67
2.66-8.21
Adjusted for gender, age, insurance groups, hospital levels, regions,
having pneumonia, having respiratory failure, and intravenous
immunoglobulin treatment
www.neurosciencesjournal.org
289
CH,
Tseng
HF.
Nationwide
population-based
Related articles
290
www.neurosciencesjournal.org